Quercetin supplementation for people with fibrotic interstitial lung disease
Study on the Efficacy of Quercetin Intake in Patients With Idiopathic Pulmonary Fibrosis and Non-Idiopathic Pulmonary Fibrosis. A Two-arm, Prospective Randomized Controlled Clinical Trial.
This research will try whether taking 500 mg/day of quercetin in two 12-week cycles can change telomere length, reduce signs of cellular aging, and affect lung function in people with IPF and other fibrotic interstitial lung diseases.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Crete Academic / other |
| Locations | 1 site (Heraklion, Crete) |
| Trial ID | NCT07466420 on ClinicalTrials.gov |
What this trial studies
This is a randomized, controlled trial enrolling 100 patients with idiopathic pulmonary fibrosis (IPF) or other fibrotic interstitial lung diseases to test oral quercetin versus usual care. Participants randomized to the quercetin arm will take 500 mg/day for two 12-week treatment cycles separated by an 8-week washout period, while all subjects may continue approved antifibrotic therapies. Primary biologic endpoints include telomere length and senescence-associated secretory phenotype (SASP) factors, with lung function measured over the treatment period. The trial is conducted at the Respiratory Department of the University Hospital of Heraklion, University of Crete.
Who should consider this trial
Good fit: Adults with a confirmed diagnosis of IPF or other fibrotic interstitial lung disease who can continue standard antifibrotic therapy and meet study screening criteria are appropriate candidates.
Not a fit: Patients with elevated exhaled nitric oxide (FeNO > 25 ppb), those unable to start quercetin within one week of baseline, or those unlikely to benefit from senolytic approaches may not receive benefit from this intervention.
Why it matters
Potential benefit: If successful, quercetin could lower markers of cellular senescence and help preserve or slow decline in lung function for patients with fibrotic ILDs.
How similar studies have performed: Preclinical work and small early-phase studies of senolytic combinations that include quercetin (often with dasatinib) have shown promising signals, but quercetin-alone trials in fibrotic lung disease are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study. * The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as standard of care. Exclusion Criteria: * Subjects with a result of FeNO\>25 ppb will be excluded from the study to ensure that no other pulmonary diseases, such as asthma, are present. * Patients who do not initiate quercetin within the first week after their baseline visit.
Where this trial is running
Heraklion, Crete
- Respiratory Department, University Hospital of Heraklion, School of Medicine, University of Crete — Heraklion, Crete, Greece (Recruiting)
Study contacts
- Principal investigator: Katerina M. Antoniou, MD PhD, Professor — Department of Respiratory Medicine, University Hospital of Heraklion, School of Medicine, University of Crete
- Study coordinator: Ioanna Argyriou, MSc
- Email: ioannaar07@gmail.com
- Phone: +302810371966
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.